Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma Outside the Fray As Obama Re-Evaluates Bush’s Pre-emption Policy

Executive Summary

The good news for drug firms about President Obama's memo curtailing federal pre-emption state laws: it won't have any real impact on industry. The bad news: it won't matter because pre-emption in the Rx arena was already dealt a body blow in the Supreme Court's recent ruling in Wyeth v. Levine
Advertisement

Related Content

FDA Housekeeping: Preemption Sweep From Regs
Pre-emption: Obama Administration Creeps Towards Reversing FDA Stance
Pre-emption After Supreme Court Ruling May Depend On How FDA Weighs Risk
Pre-emption After Supreme Court Ruling May Depend On How FDA Weighs Risk

Topics

Advertisement
UsernamePublicRestriction

Register

PS051102

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel